Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss

Brief Summary:

  • Wegovy® HD is now available on GoodRx at a self-pay price of $399 per month
  • Pricing scales to $798 for two-month supply and $1,197 for three-month supply
  • Available at pharmacies nationwide through GoodRx
  • Consumers can determine eligibility and obtain a prescription through GoodRx for Weight Loss

GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.